Compare EEX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | JANX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 821 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.7M | 790.3M |
| IPO Year | N/A | 2021 |
| Metric | EEX | JANX |
|---|---|---|
| Price | $4.68 | $15.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $7.70 | ★ $53.60 |
| AVG Volume (30 Days) | 19.0K | ★ 942.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | $236.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.32 | $12.12 |
| 52 Week High | $5.45 | $35.34 |
| Indicator | EEX | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 63.55 |
| Support Level | $4.53 | $13.10 |
| Resistance Level | $5.01 | $15.49 |
| Average True Range (ATR) | 0.16 | 0.57 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 67.50 | 88.31 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.